-
Posted by
Two Blokes Jun 12 -
Filed in
Stock
-
6 views
After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.
